Summary
Breast cancers analysed for oestrogen receptor activity over a ten-year period have been surveyed in order to select a group of intraduct carcinomas without invasion and a second, control group of invasive carcinomas without intraduct carcinoma. Examination of histological sections taken from the face of the tumour samples used for receptor analysis showed only 13 purely intraduct carcinomas without any invasion. Each of these was matched for age, menstrual status, hospital of origin, and approximate assay date with two purely invasive ductal carcinomas of no specialized type (26 invasive carcinomas in all).
In invasive carcinomas, a significantly higher proportion of the specimen was occupied by malignant cells (mean 30%) than in the intraduct carcinomas (mean 15%), and receptors were detected more frequently (77% versus 46%) and at higher concentrations (mean 26 times on a wet weight basis, 19 times on a protein basis). When allowance was made for the difference in cellularity between the groups, the invasive carcinomas still contained significantly higher concentrations of receptor protein (mean = ten times more on a wet weight basis).
These findings suggest that the expression of the gene encoding the receptor protein tends to be a property either maintained, or acquired upon progression to invasive disease. Further studies will be needed to determine whether or not the established prognostic and predictive values of receptor measurements apply to non-invasive disease, and to clarify the relationship between receptor expression in benign and malignant breast in relation to morphological changes.
References
Gump FE: Premalignant diseases of the breast. Surg Clinics N America 64: 1051–1059, 1984
Thomas DB: Factors that promote the development of human breast cancer. Environ Health Perspect 50: 209–218, 1983
Dixon JM, Page DL, Anderson TJ, Lee D, Elton RA, Stewart HJ, Forrest APM: Long term survivors after breast cancer. Br J Surg 72: 445–448, 1985
Howell A, Barnes DM, Harland RNL, Redford J, Bramwell VHT, Wilkinson MJS, Swindell R, Crowther D, Sellwood RA: Steroid hormone receptors and survival after first relapse in breast cancer. Lancet i: 573, 1984
Stewart H, Prescott R: Adjuvant tamoxifen therapy and receptor levels. Lancet i: 573, 1985
Jensen EV: Estrogen receptors in hormone-dependent breast cancers. Cancer Res 35: 3362–3364, 1985
Hawkins RA, Black R, Steele RJC, Dixon JMJ, Forrest APM: Oestrogen receptor concentration in primary breast cancer and axillary node metastases. Breast Cancer Res Treat 1: 245–251, 1981
Mignot L, Espie M, de Roquancourt A, Gorins A: Les récepteurs hormonaux et les lésions pré-cancéreuses du sein. Pathol Biol (Paris) 31: 761–764, 1983
King WJ, de Sombre ER, Jensen EV, Greene GL: Comparison of immunocytochemical and steroid-binding assays for estrogen receptor in human breast tumours. Cancer Res 45: 293–304, 1985
Hawkins RA, Sangster K, Krajewski A: Histochemical detection of oestrogen receptors in breast carcinoma: a successful technique. Br J Cancer 53: 407–401, 1986
Fisher ER, Fisher MD, Osborne CK, McGuire WL, Redmond C, Knight WM, Fisher B, Bannayan G, Walder A, Gregory EJ, Jacobsen A, Queen DM, Bennett DE, Ford HC: Correlation of primary breast cancer histopathology and estrogen receptor content. Breast Cancer Res Treat 1: 37–41, 1981
Shousha S, Backhouse CM, Alaghband-Zadeh J, Burn I: Alveolar variant of invasive lobular carcinoma of the breast. A tumour rich in oestrogen receptors. Am J Clin Pathol 85: 1–5, 1985
McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr: Estrogen receptor analyses: Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109: 716–721, 1985
Charpin C, Martin PM, Jacquemier J, Lavaut MN, Pourreau-Schneider N, Toga M: Estrogen receptor immunocytochemical assay (ER-ICA): computerised image analysis system, immunoelectron microscopy, and comparisons with estradiol binding assays in 115 breast carcinomas. Cancer Res 46 (Suppl): 4271s-4277s, 1986
Cikes M: Expression of hormone receptors in cancer cells: a hypothesis. Eur J Cancer 14: 211–215, 1978
Israel L, Band P: Hormones as growth factors. Lancet ii: 843–844, 1984
Sluyser M, Mester J: Oncogenes homologous to steroid receptors? Nature 315: 546, 1985
Bishop JM: Oncogenes as hormone receptors. Nature 321: 112–113, 1986
Kodama F, Greene GL, Salmon SE: Relation of receptor expression to clonal growth and antiestrogen effects on human breast cancer cells. Cancer Res 45: 2720–2724, 1985
Cuzick J, Wang DY, Bulbrook RD: The prevention of breast cancer. Lancet i: 83–86, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hawkins, R.A., Tesdale, A.L., Ferguson, W.A. et al. Oestrogen receptor activity in intraduct and invasive breast carcinomas. Breast Cancer Res Tr 9, 129–133 (1987). https://doi.org/10.1007/BF01807365
Issue Date:
DOI: https://doi.org/10.1007/BF01807365